Perspective Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Perspective Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than almost all Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 423% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-2.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 60% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +314%In 3 years sales changed by -100% while total assets changed by +314%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-1,472.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than almost all Healthcare companies in United States.
Cash Cushion Ratio
+55%Cash, after subtracting all debt, equals 55% of its market value (net cash).
Higher than 78% of Healthcare companies in United States.
Tangible Assets Ratio
85%Of every $100 the company owns, $85 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 56% of Healthcare companies in United States.
Tangible Net Worth Ratio
81%Of every $100 of net worth, $81 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 62% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Perspective Therapeutics, Inc. made a loss over the last year. Perspective Therapeutics, Inc. owes $0.17 for every $1 it owns. Perspective Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPerspective Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.80The share price is 0.80 times Perspective Therapeutics, Inc.'s book value per share, lower than 84% of Healthcare companies in United States.
Market cap
$258 MThe total market value of all of Perspective Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 54% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$324 MWhat Perspective Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.84Net worth divided by the number of shares. The share price of $2.26 is 0.8 times this, which is the P/B above.
Return on equity (ROE)
-39.6%Perspective Therapeutics, Inc. lost 39.6% of its shareholders' money over the last year, higher than 55% of Healthcare companies in United States.
Owes vs Owns
0.17×Perspective Therapeutics, Inc. owes $0.17 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Dividend yield
NonePerspective Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossPerspective Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredPerspective Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashPerspective Therapeutics, Inc. held $141 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Perspective Therapeutics, Inc.: $258 M ÷ $324 M (30 Jun 2026) = 0.8.
What is Perspective Therapeutics, Inc.'s return on equity?
Perspective Therapeutics, Inc. lost 39.6% of its shareholders' money over the last year, higher than 55% of Healthcare companies in United States.
How much does Perspective Therapeutics, Inc. owe compared with what it owns?
Perspective Therapeutics, Inc. owes $0.17 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Does Perspective Therapeutics, Inc. pay a dividend?
No. Perspective Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.